Company Filing History:
Years Active: 2020
Title: Luckas Ruettiger: Innovator in Tinnitus Treatment
Introduction
Luckas Ruettiger is a notable inventor based in Kusterdingen, Germany. He has made significant contributions to the field of auditory health, particularly in the treatment of tinnitus. His innovative approach focuses on the modulation of chloride co-transporter NKCC1, which plays a crucial role in auditory function.
Latest Patents
Luckas Ruettiger holds a patent for the "Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system." This invention relates to the treatment or prevention of tinnitus by utilizing a compound that modulates the chloride co-transporter NKCC1. The patent outlines pharmaceutical compositions that include this modulator as an active agent, methods for administering the modulator, and screening methods for identifying compounds capable of modulating NKCC1. He has 1 patent to his name.
Career Highlights
Luckas Ruettiger is associated with Otolanum AG, a company dedicated to advancing treatments for auditory disorders. His work at Otolanum AG has positioned him as a key player in the development of innovative therapies for tinnitus.
Collaborations
Luckas collaborates with Marlies Knipper-Breer, contributing to the research and development efforts at Otolanum AG. Their combined expertise enhances the potential for breakthroughs in tinnitus treatment.
Conclusion
Luckas Ruettiger's innovative work in the treatment of tinnitus through the modulation of NKCC1 represents a significant advancement in auditory health. His contributions continue to pave the way for new therapeutic options for individuals suffering from this challenging condition.